FDA grants breakthrough status to Augurex’s SPINEstat test to advance early axSpA diagnosis

Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US

Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs

BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus

Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions

FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes

This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms

FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma

The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability

Sigachi Industries posts Q2 FY2026 consolidated profit at Rs. 10.68 Cr

Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025

Zydus receives approval from Health Canada for Mesalamine suppositories

Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis

Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors

Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile

Laurus Labs posts Q2 FY26 consolidated PAT higher at Rs. 195 Cr

Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025

Lupin launches authorized generic of Ravicti in US

The product is indicated for the chronic management of patients with Urea Cycle Disorders